Will regulatory T cells provide needed therapies against inflammatory and autoimmune disorders?
Therapeutic applications of T cells have been focused up until now on their role as immunological ‘attack dogs’ that can be trained to seek and destroy foreign invaders or malignant growths. This core concept underlies chimeric antigen receptor (CAR)-T cell therapies that are now delivering curative treatments for some blood cancers. But Sonoma Biotherapeutics is trying to do the opposite—to harness regulatory T (Treg) cells to suppress rather than provoke an immune response, potentially offering safe and durable control for various inflammatory and autoimmune conditions.